---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126288"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:59:47.750987+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Equillium Q3 revenue $12.2M, net loss near zero; retains itolizumab rights after Ono termination

## Summary
- Q3 revenue $12.2M (up 37% YoY) from Ono partnership; net loss ~$7,000 vs $3.7M loss in Q3 2023.
- Cash $25.9M; sufficient into Q4 2025 assuming accelerated EQUATOR study, pausing EQ101/EQ302, and cost reductions.
- Ono partnership ended after substantial non-dilutive funding; Equillium retains full rights to itolizumab.
- Phase 3 EQUATOR aGVHD study enrollment paused; potential topline acceleration to Q1 2025.
- Partner Biocon completed Phase 2 ulcerative colitis study; topline data expected Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-126288
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/0000950170-24-126288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/eq-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126288
- JSON: https://secwatch.observer/filing/0000950170-24-126288.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.